Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00539669 |
Evaluate response rate of Docetaxel in combination with Carboplatin or Cisplatin as first line chemotherapy in epithelial ovarian cancer. Assess the progression free survival, tolerance, duration of response and survival in the same patient population.
Condition | Intervention | Phase |
---|---|---|
Ovarian Neoplasms |
Drug: Docetaxel |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Parallel Assignment |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | XRP6976I_2502 |
Study First Received: | October 3, 2007 |
Last Updated: | October 3, 2007 |
ClinicalTrials.gov Identifier: | NCT00539669 |
Health Authority: | Korea: Food and Drug Administration |
Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female Endocrine System Diseases Urogenital Neoplasms Ovarian Diseases |
Carboplatin Genital Diseases, Female Docetaxel Cisplatin Endocrinopathy Endocrine Gland Neoplasms |
Neoplasms Neoplasms by Site Adnexal Diseases |